Related Experiment Videos
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs
Abstract:
With a direct in vitro tumor-colony assay developed to measure sensitity of human-tumor stem cells to anticancer drugs, we performed 32 retrospective or prospective clinical studies in nine patients with myeloma and nine with ovarian cancer treated with standard agents that were tested in vitro. The results were clearly correlated (P is less than 0.00001). Unique patterns of sensitivity and resistance to the six drugs tested were observed for individual patients. In eight cases of myeloma and three of obarian carcinoma in vitro sensitivity corresponded with in vivo sensitivity whereas in one case of myeloma it did not. In vitro resistance correlated with clinical resistance in all five comparisons in myeloma and all 15 in ovarian cancer. We conclude that this assay shows sufficient promise to warrant larger-scale testing to determine its efficacy for selection of new agents and individualized cancer chemotherapy regimens.
Insights
This study shows a new in vitro tumor-colony assay accurately predicts patient response to cancer drugs. This method holds promise for selecting effective individualized chemotherapy regimens.
Area of Science:
- Oncology
- Cancer Research
- Pharmacology
Background:
- Developing predictive assays for anticancer drug efficacy is crucial for personalized medicine.
- Current methods for assessing drug sensitivity in human tumors have limitations.
Purpose of the Study:
- To evaluate a direct in vitro tumor-colony assay for measuring human tumor stem cell sensitivity to anticancer drugs.
- To correlate in vitro drug sensitivity with in vivo clinical outcomes in patients with myeloma and ovarian cancer.
Main Methods:
- A direct in vitro tumor-colony assay was developed to assess drug sensitivity.
- 32 retrospective and prospective clinical studies were conducted in 9 myeloma and 9 ovarian cancer patients.
- Standard chemotherapeutic agents tested in vitro were administered to patients.
Main Results:
- A strong correlation (P < 0.00001) was observed between in vitro drug sensitivity and in vivo clinical response.
- Individualized patterns of drug sensitivity and resistance were identified for each patient.
- In vitro resistance accurately predicted clinical resistance in all tested cases for both myeloma and ovarian cancer.
Conclusions:
- The direct in vitro tumor-colony assay demonstrates significant promise for predicting patient response to chemotherapy.
- This assay could be valuable for selecting novel anticancer agents and tailoring individualized chemotherapy regimens.
- Larger-scale validation studies are warranted to confirm the assay's clinical utility.